Overview

A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma

Status:
Not yet recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

This study is a multi-center, open-label, single-arm, non-randomized phase II clinical study in order to evaluate the safety and efficacy of zanubrutinib, lenalidomide plus R-CHOP (ZR2-CHOP) as the first-line therapy for treatment-naive high-risk diffuse large B-cell lymphoma patients.

Phase:

Phase 2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

Cyclophosphamide
Doxorubicin
Lenalidomide
Prednisone
Rituximab
Vincristine
Zanubrutinib